Alphatec Holdings, Inc. (NASDAQ:ATEC) Shares Purchased by First Eagle Investment Management LLC

First Eagle Investment Management LLC lifted its position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 36.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 658,437 shares of the medical technology company's stock after purchasing an additional 176,402 shares during the quarter. First Eagle Investment Management LLC owned 0.46% of Alphatec worth $6,044,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in ATEC. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in Alphatec by 11.3% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company's stock valued at $16,280,000 after acquiring an additional 297,850 shares during the period. Barclays PLC grew its stake in Alphatec by 362.3% in the 3rd quarter. Barclays PLC now owns 170,546 shares of the medical technology company's stock valued at $948,000 after acquiring an additional 133,653 shares during the period. Franklin Resources Inc. grew its stake in Alphatec by 299.3% in the 3rd quarter. Franklin Resources Inc. now owns 64,450 shares of the medical technology company's stock valued at $343,000 after acquiring an additional 48,308 shares during the period. Royce & Associates LP grew its stake in Alphatec by 15.9% in the 3rd quarter. Royce & Associates LP now owns 1,212,286 shares of the medical technology company's stock valued at $6,740,000 after acquiring an additional 165,954 shares during the period. Finally, State Street Corp grew its stake in Alphatec by 10.1% in the 3rd quarter. State Street Corp now owns 3,138,960 shares of the medical technology company's stock valued at $17,453,000 after acquiring an additional 287,350 shares during the period. Institutional investors and hedge funds own 66.35% of the company's stock.

Remove Ads

Alphatec Trading Up 6.9 %

Shares of ATEC stock traded up $0.66 during trading on Thursday, hitting $10.20. 1,712,909 shares of the stock traded hands, compared to its average volume of 1,975,562. The firm has a market capitalization of $1.47 billion, a P/E ratio of -7.97 and a beta of 1.39. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $14.88. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The firm's fifty day moving average price is $10.95 and its 200-day moving average price is $8.80.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.04). The business had revenue of $176.79 million during the quarter, compared to analyst estimates of $172.74 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. As a group, research analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Insider Buying and Selling at Alphatec

In other Alphatec news, EVP David Sponsel sold 58,283 shares of the business's stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $10.71, for a total value of $624,210.93. Following the sale, the executive vice president now owns 502,311 shares of the company's stock, valued at $5,379,750.81. The trade was a 10.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Patrick Miles sold 50,000 shares of Alphatec stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $12.03, for a total value of $601,500.00. Following the completion of the sale, the chief executive officer now directly owns 6,152,544 shares of the company's stock, valued at $74,015,104.32. The trade was a 0.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 337,321 shares of company stock worth $3,828,060 over the last three months. Insiders own 22.80% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on ATEC. Piper Sandler lifted their price target on shares of Alphatec from $12.00 to $13.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 target price on shares of Alphatec in a research note on Tuesday, January 14th. StockNews.com raised shares of Alphatec from a "sell" rating to a "hold" rating in a research note on Friday, February 28th. Needham & Company LLC reaffirmed a "buy" rating and set a $16.00 target price on shares of Alphatec in a research note on Thursday, February 27th. Finally, Barclays lifted their target price on shares of Alphatec from $20.00 to $21.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 22nd. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $17.67.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.